世界のヘテロ接合性家族性高コレステロール血症薬市場インサイト及び予測(~2026年)

【英語タイトル】Global Heterozygous Familial Hypercholesterolemia Drug Market Insights and Forecast to 2026

QYResearchが出版した調査資料(QYR20NV01147)・商品コード:QYR20NV01147
・発行会社(調査会社):QYResearch
・発行日:2020年11月(※2024年版があります。お問い合わせください)
・ページ数:112
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医療、製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートはヘテロ接合性家族性高コレステロール血症薬の世界市場について調査・分析した資料です。種類別(ジェムカベンカルシウム、MGL-3196、ST-103、その他)の市場規模、用途別(クリニック、病院、その他)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別ヘテロ接合性家族性高コレステロール血症薬の競争状況、市場シェア
・世界のヘテロ接合性家族性高コレステロール血症薬市場:種類別市場規模 2015年-2020年(ジェムカベンカルシウム、MGL-3196、ST-103、その他)
・世界のヘテロ接合性家族性高コレステロール血症薬市場:種類別市場規模予測 2021年-2026年(ジェムカベンカルシウム、MGL-3196、ST-103、その他)
・世界のヘテロ接合性家族性高コレステロール血症薬市場:用途別市場規模 2015年-2020年(クリニック、病院、その他)
・世界のヘテロ接合性家族性高コレステロール血症薬市場:用途別市場規模予測 2021年-2026年(クリニック、病院、その他)
・北米のヘテロ接合性家族性高コレステロール血症薬市場分析:米国、カナダ
・ヨーロッパのヘテロ接合性家族性高コレステロール血症薬市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアのヘテロ接合性家族性高コレステロール血症薬市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米のヘテロ接合性家族性高コレステロール血症薬市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカのヘテロ接合性家族性高コレステロール血症薬市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Daewoong Co Ltd、Esperion Therapeutics Inc、Gemphire Therapeutics Inc、Madrigal Pharmaceuticals Inc
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

Market Analysis and Insights: Global Heterozygous Familial Hypercholesterolemia Drug Market
The global Heterozygous Familial Hypercholesterolemia Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Heterozygous Familial Hypercholesterolemia Drug Scope and Market Size
Heterozygous Familial Hypercholesterolemia Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Heterozygous Familial Hypercholesterolemia Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Heterozygous Familial Hypercholesterolemia Drug market is segmented into
Gemcabene Calcium
MGL-3196
ST-103
Others

Segment by Application, the Heterozygous Familial Hypercholesterolemia Drug market is segmented into
Clinic
Hospital
Others

Regional and Country-level Analysis
The Heterozygous Familial Hypercholesterolemia Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Heterozygous Familial Hypercholesterolemia Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Heterozygous Familial Hypercholesterolemia Drug Market Share Analysis
Heterozygous Familial Hypercholesterolemia Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Heterozygous Familial Hypercholesterolemia Drug business, the date to enter into the Heterozygous Familial Hypercholesterolemia Drug market, Heterozygous Familial Hypercholesterolemia Drug product introduction, recent developments, etc.

The major vendors covered:
Daewoong Co Ltd
Esperion Therapeutics Inc
Gemphire Therapeutics Inc
Madrigal Pharmaceuticals Inc

【レポートの目次】

1 Study Coverage
1.1 Heterozygous Familial Hypercholesterolemia Drug Product Introduction
1.2 Market Segments
1.3 Key Heterozygous Familial Hypercholesterolemia Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Heterozygous Familial Hypercholesterolemia Drug Market Size Growth Rate by Type
1.4.2 Gemcabene Calcium
1.4.3 MGL-3196
1.4.4 ST-103
1.4.5 Others
1.5 Market by Application
1.5.1 Global Heterozygous Familial Hypercholesterolemia Drug Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Heterozygous Familial Hypercholesterolemia Drug Market Size, Estimates and Forecasts
2.1.1 Global Heterozygous Familial Hypercholesterolemia Drug Revenue 2015-2026
2.1.2 Global Heterozygous Familial Hypercholesterolemia Drug Sales 2015-2026
2.2 Global Heterozygous Familial Hypercholesterolemia Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Heterozygous Familial Hypercholesterolemia Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Heterozygous Familial Hypercholesterolemia Drug Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Heterozygous Familial Hypercholesterolemia Drug Competitor Landscape by Players
3.1 Heterozygous Familial Hypercholesterolemia Drug Sales by Manufacturers
3.1.1 Heterozygous Familial Hypercholesterolemia Drug Sales by Manufacturers (2015-2020)
3.1.2 Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Heterozygous Familial Hypercholesterolemia Drug Revenue by Manufacturers
3.2.1 Heterozygous Familial Hypercholesterolemia Drug Revenue by Manufacturers (2015-2020)
3.2.2 Heterozygous Familial Hypercholesterolemia Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Heterozygous Familial Hypercholesterolemia Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Heterozygous Familial Hypercholesterolemia Drug Revenue in 2019
3.2.5 Global Heterozygous Familial Hypercholesterolemia Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Heterozygous Familial Hypercholesterolemia Drug Price by Manufacturers
3.4 Heterozygous Familial Hypercholesterolemia Drug Manufacturing Base Distribution, Product Types
3.4.1 Heterozygous Familial Hypercholesterolemia Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Heterozygous Familial Hypercholesterolemia Drug Product Type
3.4.3 Date of International Manufacturers Enter into Heterozygous Familial Hypercholesterolemia Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Heterozygous Familial Hypercholesterolemia Drug Market Size by Type (2015-2020)
4.1.1 Global Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2015-2020)
4.1.2 Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Type (2015-2020)
4.1.3 Heterozygous Familial Hypercholesterolemia Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Heterozygous Familial Hypercholesterolemia Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Heterozygous Familial Hypercholesterolemia Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Heterozygous Familial Hypercholesterolemia Drug Revenue Forecast by Type (2021-2026)
4.2.3 Heterozygous Familial Hypercholesterolemia Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Heterozygous Familial Hypercholesterolemia Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Heterozygous Familial Hypercholesterolemia Drug Market Size by Application (2015-2020)
5.1.1 Global Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2015-2020)
5.1.2 Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Application (2015-2020)
5.1.3 Heterozygous Familial Hypercholesterolemia Drug Price by Application (2015-2020)
5.2 Heterozygous Familial Hypercholesterolemia Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Heterozygous Familial Hypercholesterolemia Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Heterozygous Familial Hypercholesterolemia Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Heterozygous Familial Hypercholesterolemia Drug Price Forecast by Application (2021-2026)

6 North America
6.1 North America Heterozygous Familial Hypercholesterolemia Drug by Country
6.1.1 North America Heterozygous Familial Hypercholesterolemia Drug Sales by Country
6.1.2 North America Heterozygous Familial Hypercholesterolemia Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Heterozygous Familial Hypercholesterolemia Drug Market Facts & Figures by Type
6.3 North America Heterozygous Familial Hypercholesterolemia Drug Market Facts & Figures by Application

7 Europe
7.1 Europe Heterozygous Familial Hypercholesterolemia Drug by Country
7.1.1 Europe Heterozygous Familial Hypercholesterolemia Drug Sales by Country
7.1.2 Europe Heterozygous Familial Hypercholesterolemia Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Heterozygous Familial Hypercholesterolemia Drug Market Facts & Figures by Type
7.3 Europe Heterozygous Familial Hypercholesterolemia Drug Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Heterozygous Familial Hypercholesterolemia Drug by Region
8.1.1 Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Sales by Region
8.1.2 Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Market Facts & Figures by Type
8.3 Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Market Facts & Figures by Application

9 Latin America
9.1 Latin America Heterozygous Familial Hypercholesterolemia Drug by Country
9.1.1 Latin America Heterozygous Familial Hypercholesterolemia Drug Sales by Country
9.1.2 Latin America Heterozygous Familial Hypercholesterolemia Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Heterozygous Familial Hypercholesterolemia Drug Market Facts & Figures by Type
9.3 Central & South America Heterozygous Familial Hypercholesterolemia Drug Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug by Country
10.1.1 Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales by Country
10.1.2 Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Market Facts & Figures by Type
10.3 Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Market Facts & Figures by Application

11 Company Profiles
11.1 Daewoong Co Ltd
11.1.1 Daewoong Co Ltd Corporation Information
11.1.2 Daewoong Co Ltd Description and Business Overview
11.1.3 Daewoong Co Ltd Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Products Offered
11.1.5 Daewoong Co Ltd Related Developments
11.2 Esperion Therapeutics Inc
11.2.1 Esperion Therapeutics Inc Corporation Information
11.2.2 Esperion Therapeutics Inc Description and Business Overview
11.2.3 Esperion Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Esperion Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Products Offered
11.2.5 Esperion Therapeutics Inc Related Developments
11.3 Gemphire Therapeutics Inc
11.3.1 Gemphire Therapeutics Inc Corporation Information
11.3.2 Gemphire Therapeutics Inc Description and Business Overview
11.3.3 Gemphire Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Gemphire Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Products Offered
11.3.5 Gemphire Therapeutics Inc Related Developments
11.4 Madrigal Pharmaceuticals Inc
11.4.1 Madrigal Pharmaceuticals Inc Corporation Information
11.4.2 Madrigal Pharmaceuticals Inc Description and Business Overview
11.4.3 Madrigal Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Madrigal Pharmaceuticals Inc Heterozygous Familial Hypercholesterolemia Drug Products Offered
11.4.5 Madrigal Pharmaceuticals Inc Related Developments
11.1 Daewoong Co Ltd
11.1.1 Daewoong Co Ltd Corporation Information
11.1.2 Daewoong Co Ltd Description and Business Overview
11.1.3 Daewoong Co Ltd Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Products Offered
11.1.5 Daewoong Co Ltd Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Heterozygous Familial Hypercholesterolemia Drug Market Estimates and Projections by Region
12.1.1 Global Heterozygous Familial Hypercholesterolemia Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Heterozygous Familial Hypercholesterolemia Drug Revenue Forecast by Regions 2021-2026
12.2 North America Heterozygous Familial Hypercholesterolemia Drug Market Size Forecast (2021-2026)
12.2.1 North America: Heterozygous Familial Hypercholesterolemia Drug Sales Forecast (2021-2026)
12.2.2 North America: Heterozygous Familial Hypercholesterolemia Drug Revenue Forecast (2021-2026)
12.2.3 North America: Heterozygous Familial Hypercholesterolemia Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Heterozygous Familial Hypercholesterolemia Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Heterozygous Familial Hypercholesterolemia Drug Sales Forecast (2021-2026)
12.3.2 Europe: Heterozygous Familial Hypercholesterolemia Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Heterozygous Familial Hypercholesterolemia Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Heterozygous Familial Hypercholesterolemia Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Heterozygous Familial Hypercholesterolemia Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Heterozygous Familial Hypercholesterolemia Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Heterozygous Familial Hypercholesterolemia Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Heterozygous Familial Hypercholesterolemia Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Heterozygous Familial Hypercholesterolemia Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Heterozygous Familial Hypercholesterolemia Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Heterozygous Familial Hypercholesterolemia Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Heterozygous Familial Hypercholesterolemia Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Heterozygous Familial Hypercholesterolemia Drug Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Heterozygous Familial Hypercholesterolemia Drug Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Heterozygous Familial Hypercholesterolemia Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Heterozygous Familial Hypercholesterolemia Drug Market Segments
Table 2. Ranking of Global Top Heterozygous Familial Hypercholesterolemia Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Heterozygous Familial Hypercholesterolemia Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Gemcabene Calcium
Table 5. Major Manufacturers of MGL-3196
Table 6. Major Manufacturers of ST-103
Table 7. Major Manufacturers of Others
Table 8. Global Heterozygous Familial Hypercholesterolemia Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 9. Global Heterozygous Familial Hypercholesterolemia Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 10. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Regions 2015-2020 (K Pcs)
Table 11. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Regions (2015-2020)
Table 12. Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Regions 2015-2020 (US$ Million)
Table 13. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 14. Global Heterozygous Familial Hypercholesterolemia Drug Sales Share by Manufacturers (2015-2020)
Table 15. Global Heterozygous Familial Hypercholesterolemia Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 16. Global Heterozygous Familial Hypercholesterolemia Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Heterozygous Familial Hypercholesterolemia Drug as of 2019)
Table 17. Heterozygous Familial Hypercholesterolemia Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 18. Heterozygous Familial Hypercholesterolemia Drug Revenue Share by Manufacturers (2015-2020)
Table 19. Key Manufacturers Heterozygous Familial Hypercholesterolemia Drug Price (2015-2020) (USD/Pcs)
Table 20. Heterozygous Familial Hypercholesterolemia Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 21. Manufacturers Heterozygous Familial Hypercholesterolemia Drug Product Type
Table 22. Date of International Manufacturers Enter into Heterozygous Familial Hypercholesterolemia Drug Market
Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 24. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2015-2020) (K Pcs)
Table 25. Global Heterozygous Familial Hypercholesterolemia Drug Sales Share by Type (2015-2020)
Table 26. Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Type (2015-2020) (US$ Million)
Table 27. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Share by Type (2015-2020)
Table 28. Heterozygous Familial Hypercholesterolemia Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 29. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2015-2020) (K Pcs)
Table 30. Global Heterozygous Familial Hypercholesterolemia Drug Sales Share by Application (2015-2020)
Table 31. North America Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2015-2020) (K Pcs)
Table 32. North America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Country (2015-2020)
Table 33. North America Heterozygous Familial Hypercholesterolemia Drug Revenue by Country (2015-2020) (US$ Million)
Table 34. North America Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Country (2015-2020)
Table 35. North America Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2015-2020) (K Pcs)
Table 36. North America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Type (2015-2020)
Table 37. North America Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2015-2020) (K Pcs)
Table 38. North America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Application (2015-2020)
Table 39. Europe Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2015-2020) (K Pcs)
Table 40. Europe Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Country (2015-2020)
Table 41. Europe Heterozygous Familial Hypercholesterolemia Drug Revenue by Country (2015-2020) (US$ Million)
Table 42. Europe Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Country (2015-2020)
Table 43. Europe Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2015-2020) (K Pcs)
Table 44. Europe Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Type (2015-2020)
Table 45. Europe Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2015-2020) (K Pcs)
Table 46. Europe Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Application (2015-2020)
Table 47. Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Sales by Region (2015-2020) (K Pcs)
Table 48. Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Region (2015-2020)
Table 49. Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Revenue by Region (2015-2020) (US$ Million)
Table 50. Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Region (2015-2020)
Table 51. Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2015-2020) (K Pcs)
Table 52. Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Type (2015-2020)
Table 53. Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2015-2020) (K Pcs)
Table 54. Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Application (2015-2020)
Table 55. Latin America Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2015-2020) (K Pcs)
Table 56. Latin America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Country (2015-2020)
Table 57. Latin Americaa Heterozygous Familial Hypercholesterolemia Drug Revenue by Country (2015-2020) (US$ Million)
Table 58. Latin America Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Country (2015-2020)
Table 59. Latin America Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2015-2020) (K Pcs)
Table 60. Latin America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Type (2015-2020)
Table 61. Latin America Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2015-2020) (K Pcs)
Table 62. Latin America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Application (2015-2020)
Table 63. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2015-2020) (K Pcs)
Table 64. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Country (2015-2020)
Table 65. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Revenue by Country (2015-2020) (US$ Million)
Table 66. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Country (2015-2020)
Table 67. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2015-2020) (K Pcs)
Table 68. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Type (2015-2020)
Table 69. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2015-2020) (K Pcs)
Table 70. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Application (2015-2020)
Table 71. Daewoong Co Ltd Corporation Information
Table 72. Daewoong Co Ltd Description and Major Businesses
Table 73. Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 74. Daewoong Co Ltd Product
Table 75. Daewoong Co Ltd Recent Development
Table 76. Esperion Therapeutics Inc Corporation Information
Table 77. Esperion Therapeutics Inc Description and Major Businesses
Table 78. Esperion Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 79. Esperion Therapeutics Inc Product
Table 80. Esperion Therapeutics Inc Recent Development
Table 81. Gemphire Therapeutics Inc Corporation Information
Table 82. Gemphire Therapeutics Inc Description and Major Businesses
Table 83. Gemphire Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 84. Gemphire Therapeutics Inc Product
Table 85. Gemphire Therapeutics Inc Recent Development
Table 86. Madrigal Pharmaceuticals Inc Corporation Information
Table 87. Madrigal Pharmaceuticals Inc Description and Major Businesses
Table 88. Madrigal Pharmaceuticals Inc Heterozygous Familial Hypercholesterolemia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 89. Madrigal Pharmaceuticals Inc Product
Table 90. Madrigal Pharmaceuticals Inc Recent Development
Table 91. Global Heterozygous Familial Hypercholesterolemia Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 92. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share Forecast by Regions (2021-2026)
Table 93. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 94. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 95. North America: Heterozygous Familial Hypercholesterolemia Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 96. North America: Heterozygous Familial Hypercholesterolemia Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 97. Europe: Heterozygous Familial Hypercholesterolemia Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 98. Europe: Heterozygous Familial Hypercholesterolemia Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 99. Asia Pacific: Heterozygous Familial Hypercholesterolemia Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 100. Asia Pacific: Heterozygous Familial Hypercholesterolemia Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 101. Latin America: Heterozygous Familial Hypercholesterolemia Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 102. Latin America: Heterozygous Familial Hypercholesterolemia Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 103. Middle East and Africa: Heterozygous Familial Hypercholesterolemia Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 104. Middle East and Africa: Heterozygous Familial Hypercholesterolemia Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 105. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 106. Key Challenges
Table 107. Market Risks
Table 108. Main Points Interviewed from Key Heterozygous Familial Hypercholesterolemia Drug Players
Table 109. Heterozygous Familial Hypercholesterolemia Drug Customers List
Table 110. Heterozygous Familial Hypercholesterolemia Drug Distributors List
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Heterozygous Familial Hypercholesterolemia Drug Product Picture
Figure 2. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Gemcabene Calcium Product Picture
Figure 4. MGL-3196 Product Picture
Figure 5. ST-103 Product Picture
Figure 6. Others Product Picture
Figure 7. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Application in 2020 & 2026
Figure 8. Clinic
Figure 9. Hospital
Figure 10. Others
Figure 11. Heterozygous Familial Hypercholesterolemia Drug Report Years Considered
Figure 12. Global Heterozygous Familial Hypercholesterolemia Drug Market Size 2015-2026 (US$ Million)
Figure 13. Global Heterozygous Familial Hypercholesterolemia Drug Sales 2015-2026 (K Pcs)
Figure 14. Global Heterozygous Familial Hypercholesterolemia Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Region (2015-2020)
Figure 16. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Region in 2019
Figure 17. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Region (2015-2020)
Figure 18. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Region in 2019
Figure 19. Global Heterozygous Familial Hypercholesterolemia Drug Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Heterozygous Familial Hypercholesterolemia Drug Revenue in 2019
Figure 21. Heterozygous Familial Hypercholesterolemia Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Type (2015-2020)
Figure 23. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Type in 2019
Figure 24. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Type (2015-2020)
Figure 25. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Type in 2019
Figure 26. Global Heterozygous Familial Hypercholesterolemia Drug Market Share by Price Range (2015-2020)
Figure 27. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Application (2015-2020)
Figure 28. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Application in 2019
Figure 29. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Application (2015-2020)
Figure 30. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Application in 2019
Figure 31. North America Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 32. North America Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Country in 2019
Figure 34. North America Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Country in 2019
Figure 35. U.S. Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 36. U.S. Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 38. Canada Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Heterozygous Familial Hypercholesterolemia Drug Market Share by Type in 2019
Figure 40. North America Heterozygous Familial Hypercholesterolemia Drug Market Share by Application in 2019
Figure 41. Europe Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 42. Europe Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Country in 2019
Figure 44. Europe Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Country in 2019
Figure 45. Germany Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 46. Germany Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. France Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 50. U.K. Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. Italy Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Russia Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Heterozygous Familial Hypercholesterolemia Drug Market Share by Type in 2019
Figure 56. Europe Heterozygous Familial Hypercholesterolemia Drug Market Share by Application in 2019
Figure 57. Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 58. Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Region in 2019
Figure 60. Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Region in 2019
Figure 61. China Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 62. China Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 64. Japan Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 66. South Korea Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. India Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. Australia Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. Taiwan Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. Indonesia Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Thailand Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Malaysia Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Philippines Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Vietnam Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Market Share by Type in 2019
Figure 84. Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Market Share by Application in 2019
Figure 85. Latin America Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 86. Latin America Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Country in 2019
Figure 88. Latin America Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Country in 2019
Figure 89. Mexico Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 90. Mexico Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 92. Brazil Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Argentina Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Heterozygous Familial Hypercholesterolemia Drug Market Share by Type in 2019
Figure 96. Latin America Heterozygous Familial Hypercholesterolemia Drug Market Share by Application in 2019
Figure 97. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 98. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Country in 2019
Figure 101. Turkey Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 102. Turkey Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 104. Saudi Arabia Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 106. U.A.E Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Market Share by Type in 2019
Figure 108. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Market Share by Application in 2019
Figure 109. North America Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 110. North America Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Europe Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 112. Europe Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 114. Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Latin America Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 116. Latin America Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 118. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Porter's Five Forces Analysis
Figure 120. Channels of Distribution
Figure 121. Distributors Profiles
Figure 122. Bottom-up and Top-down Approaches for This Report
Figure 123. Data Triangulation
Figure 124. Key Executives Interviewed


【掲載企業】

Daewoong Co Ltd、Esperion Therapeutics Inc、Gemphire Therapeutics Inc、Madrigal Pharmaceuticals Inc

★調査レポート[世界のヘテロ接合性家族性高コレステロール血症薬市場インサイト及び予測(~2026年)] (コード:QYR20NV01147)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のヘテロ接合性家族性高コレステロール血症薬市場インサイト及び予測(~2026年)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆